title: Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma.
abstract: Since the development and evaluation of novel anti-cancer therapies require molecular insight in the disease state, both FDG-PET and BLI imaging were evaluated in a Burkitt B-cell lymphoma xenograft model treated with cyclophosphamide or temsirolimus. Daudi xenograft mice were treated with either cyclophosphamide or temsirolimus and imaged with BLI and FDG-PET on d0 (before treatment), d2, d4, d7, d9 and d14 following the start of therapy. Besides tumor volume changes, therapy response was assessed with immunohistochemical analysis (apoptosis). BLI revealed a flare following both therapeutics that was significantly higher when compared to control tumors. FDG-PET decreased immediatelly, long before the tumor reduced in size. Late after therapy, BLI signal intensities decreased significantly compared to baseline subsequent to tumor size reduction while apoptosis was immediately induced following both treatment regimen. Unlike FDG, BLI was not able to reflect reduced levels of viable cells and was not able to predict tumor size response and apoptosis response.
authors.affiliation: Department of Nuclear Medicine, Maastricht University Medical Centre Maastricht, The Netherlands.
authors.forename: Marijke De
authors.initials: MD
authors.lastname: Saint-Hubert
authors.forename: Ellen
authors.initials: E
authors.lastname: Devos
authors.forename: Abdelilah
authors.initials: A
authors.lastname: Ibrahimi
authors.forename: Zeger
authors.initials: Z
authors.lastname: Debyser
authors.forename: Luc
authors.initials: L
authors.lastname: Mortelmans
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
keywords: Bioluminescence imaging; FDG-PET; therapy response